𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Self-injurious behavior in neurodevelopmental disorders: Relevance of nociceptive and immune mechanisms

✍ Scribed by Frank J. Symons


Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
458 KB
Volume
35
Category
Article
ISSN
0149-7634

No coin nor oath required. For personal study only.

✦ Synopsis


Self-injurious behavior (SIB) among individuals with intellectual and related neurodevelopmental disorders (IDD) is a clinical challenge and scientific puzzle. The physiological mechanisms regulating the sensory components of SIB remain a mystery with no clear understanding of the underlying pathophysiology. The central dogma regarding sensory processing in general and pain in particular among individuals with IDD and chronic SIB is that sensory processing is reduced and pain is absent or blunted. In this paper, recent findings challenging some of the conventional wisdom regarding pain and sensory function among individuals with IDD and SIB are reviewed. It seems that at least a subgroup of individuals with IDD and chronic SIB may be in a physiological state similar to neuropathic pain in which hyperalgesia is mediated by plasticity mechanisms regulating inflammatory, immune, and nociceptive systems. In response to repeated tissue damage associated with chronic self-injury, innate immune cells may be producing pro-inflammatory and pro-nociceptive cytokines that act on the brain to cause sickness-like behavior and sensitize primary sensory nerve afferents contributing to pain hypersensitivity (i.e., hyperalgesia).


📜 SIMILAR VOLUMES


L-DOPA-induced activation of striatal p3
✍ Subbiah P. Sivam; Subbiah Pugazhenthi; Vidya Pugazhenthi; Heath Brown 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

## Abstract The destruction of nigrostriatal dopaminergic neurons with 6‐hydroxydopamine (6OHDA) during the neonatal period results in dopamine (DA) loss and susceptibility for self‐injurious behavior (SIB) when challenged with L‐dihydroxyphenylalanine (L‐DOPA), via a supersensitive D1 receptor‐med